磁性介孔纳米粒子的制备及对抗癌药紫杉醇的传输

以十六烷基溴化铵(CTAB)为结构导向剂, 正硅酸乙酯(TEOS)为硅源, 在碱性环境下经过自组装过程对单分散性磁性Fe₃O₄纳米粒子进行包覆, 制备出磁性硅基介孔纳米粒子Fe₃O₄@SiO₂. 结合X射线衍射、 傅里叶变换红外光谱(FTIR)、 透射电子显微镜(TEM)以及氮气吸附-脱附等技术对Fe₃O₄@SiO₂粒子进行表征. 结果表明Fe₃O₄@SiO₂纳米粒子具有球形形貌, 平均直径约为150 nm, 蠕虫状介孔结构, 比表面积为932 m²/g, 孔径为2.5 nm且分布较均匀, 包覆后Fe₃O₄的结构得以保持, 同时材料具有很好的磁响应能力. 以抗癌药紫杉醇(Paelitaxel, TXL)为模型药物进行负载, 实验结果表明, Fe₃O₄@SiO₂对TXL的负载能力为80 mg/g, TXL-Fe₃O₄@SiO₂对TXL的缓释时间持续120 h以上, 累积释放量达到30 mg/g. 通过噻唑蓝比色(MTT)法测量了TXL-Fe₃O₄@SiO₂粒子对体外培养的HeLa细胞的细胞毒性, 与相同浓度的TXL相比, TXL-Fe₃O₄@SiO₂对HeLa细胞的抑制率明显增高.

Fabrication and TXL Anti-cancer Drug Delivery of Magnetic Mesoporous Silica Nanoparticles†

Magnetic Fe₃O₄@SiO₂ mesoporous silica nanoparticles(MSNs) were synthesized with Fe₃O₄ nanoparticles as crystal core, cetyltrimethylammium bromide(CTAB) as structural directional agent through the hydrolysis of tetraethoxysilane(TEOS) and self-assembly procedure under the basic conditions. The synthesized MSNs were characterized via the XRD, FTIR, TEM and N₂ adsorptiom-desorption. The results show that these MSNs have high sepcific surface area of 932 cm²/g, particles size of 150 nm and typical hexagonal packing mesoporous structure. Simultaneously, all Fe₃O₄ nanoparticles are perfectly embedded in silica bulk. As a TXL carrier, Fe₃O₄@SiO₂ exhibits good adsorption with the maximum adsorption capacity of 80 mg/g and TXL-Fe₃O₄@SiO₂ has a more than 120 h sustained release for TXL with accumulative quantity of 30 mg/g. While the release behaviour is controlled by various pH values. Higher the pH is, larger the accumulative release is. Experiments of cytotoxicity on HeLa cells indicate that the Fe₃O₄@SiO₂ particles exhibit excellent biocompatibility. TXL-Fe₃O₄@SiO₂ shows significant inhibition effect on HeLa cells than bare TXL under the same drug concentration.